FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384694805> ?p ?o ?g. }

• W4384694805 endingPage "1196" @default.
• W4384694805 startingPage "1196" @default.
• W4384694805 abstract "Nearly 10% of COVID-19 cases will require admission to the intensive care unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary infections among critically ill COVID-19 adult patients treated with/without immunomodulation.A prospective observational cohort study was performed between 2020 and 2022 at a single ICU. The diagnosis and severity classification were established by the ECDC and WHO criteria, respectively. Eligible patients were included consecutively at admission, and followed for +30 days post-inclusion. Bloodstream-infections (BSIs), ventilator-associated bacterial pneumonia (VAP), and COVID-19-associated invasive pulmonary aspergillosis (CAPA) were defined according to international guidelines. Patient stratification was performed by immunomodulatory therapy administration (dexamethasone, tocilizumab, baricitinib/ruxolitinib). The primary outcome was any microbiologically confirmed major infectious complication, secondary outcomes were invasive mechanical ventilation (IMV) requirement and all-cause mortality.Altogether, 379 adults were included. At baseline, 249/379 (65.7%) required IMV and 196/379 (51.7%) had a cytokine storm. At +30 days post-inclusion, the rate of any microbiologically confirmed major infectious complication was 151/379 (39.8%), IMV requirement and all-cause mortality were 303/379 (79.9%) and 203/379 (53.6%), respectively. There were no statistically significant outcome differences after stratification. BSI, VAP, and CAPA episodes were mostly caused by Enterococcus faecalis (27/124, 22.1%), Pseudomonas aeruginosa (26/91, 28.6%), and Aspergillus fumigatus (20/20, 100%), respectively. Concerning the primary outcome, Kaplan-Meier analysis showed similar probability distributions between the treatment subgroups (118/299, 39.5% vs. 33/80, 41.3%, log-rank p = 0.22), and immunomodulation was not retained as its independent predictor in multivariate logistic regression.Secondary infections among critically ill COVID-19 adult patients represent a relevant burden, probably irrespective of immunomodulatory treatment." @default.
• W4384694805 created "2023-07-20" @default.
• W4384694805 creator A5002662322 @default.
• W4384694805 creator A5006619410 @default.
• W4384694805 creator A5012080747 @default.
• W4384694805 creator A5012507572 @default.
• W4384694805 creator A5027021089 @default.
• W4384694805 creator A5030471595 @default.
• W4384694805 creator A5037531643 @default.
• W4384694805 creator A5046014777 @default.
• W4384694805 creator A5054023245 @default.
• W4384694805 creator A5072162426 @default.
• W4384694805 creator A5083692157 @default.
• W4384694805 creator A5085755715 @default.
• W4384694805 creator A5092493848 @default.
• W4384694805 date "2023-07-17" @default.
• W4384694805 modified "2023-10-03" @default.
• W4384694805 title "Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study" @default.
• W4384694805 cites W1803784511 @default.
• W4384694805 cites W2163845781 @default.
• W4384694805 cites W2166356134 @default.
• W4384694805 cites W2599076725 @default.
• W4384694805 cites W2620241325 @default.
• W4384694805 cites W2752537900 @default.
• W4384694805 cites W2992250822 @default.
• W4384694805 cites W3043975336 @default.
• W4384694805 cites W3093693178 @default.
• W4384694805 cites W3112984291 @default.
• W4384694805 cites W3132527202 @default.
• W4384694805 cites W3136634017 @default.
• W4384694805 cites W3139014590 @default.
• W4384694805 cites W3152721206 @default.
• W4384694805 cites W3164940806 @default.
• W4384694805 cites W3172366125 @default.
• W4384694805 cites W3210870675 @default.
• W4384694805 cites W3216810195 @default.
• W4384694805 cites W4205466743 @default.
• W4384694805 cites W4213293004 @default.
• W4384694805 cites W4229443625 @default.
• W4384694805 cites W4237644445 @default.
• W4384694805 cites W4248429808 @default.
• W4384694805 cites W4289522791 @default.
• W4384694805 cites W4289545102 @default.
• W4384694805 cites W4296993868 @default.
• W4384694805 cites W4307458322 @default.
• W4384694805 cites W4307734713 @default.
• W4384694805 cites W4307810434 @default.
• W4384694805 doi "https://doi.org/10.3390/antibiotics12071196" @default.
• W4384694805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37508292" @default.
• W4384694805 hasPublicationYear "2023" @default.
• W4384694805 type Work @default.
• W4384694805 citedByCount "0" @default.
• W4384694805 crossrefType "journal-article" @default.
• W4384694805 hasAuthorship W4384694805A5002662322 @default.
• W4384694805 hasAuthorship W4384694805A5006619410 @default.
• W4384694805 hasAuthorship W4384694805A5012080747 @default.
• W4384694805 hasAuthorship W4384694805A5012507572 @default.
• W4384694805 hasAuthorship W4384694805A5027021089 @default.
• W4384694805 hasAuthorship W4384694805A5030471595 @default.
• W4384694805 hasAuthorship W4384694805A5037531643 @default.
• W4384694805 hasAuthorship W4384694805A5046014777 @default.
• W4384694805 hasAuthorship W4384694805A5054023245 @default.
• W4384694805 hasAuthorship W4384694805A5072162426 @default.
• W4384694805 hasAuthorship W4384694805A5083692157 @default.
• W4384694805 hasAuthorship W4384694805A5085755715 @default.
• W4384694805 hasAuthorship W4384694805A5092493848 @default.
• W4384694805 hasBestOaLocation W43846948051 @default.
• W4384694805 hasConcept C126322002 @default.
• W4384694805 hasConcept C177713679 @default.
• W4384694805 hasConcept C188816634 @default.
• W4384694805 hasConcept C201903717 @default.
• W4384694805 hasConcept C2776376669 @default.
• W4384694805 hasConcept C2777080012 @default.
• W4384694805 hasConcept C2777914695 @default.
• W4384694805 hasConcept C71924100 @default.
• W4384694805 hasConceptScore W4384694805C126322002 @default.
• W4384694805 hasConceptScore W4384694805C177713679 @default.
• W4384694805 hasConceptScore W4384694805C188816634 @default.
• W4384694805 hasConceptScore W4384694805C201903717 @default.
• W4384694805 hasConceptScore W4384694805C2776376669 @default.
• W4384694805 hasConceptScore W4384694805C2777080012 @default.
• W4384694805 hasConceptScore W4384694805C2777914695 @default.
• W4384694805 hasConceptScore W4384694805C71924100 @default.
• W4384694805 hasFunder F4320321102 @default.
• W4384694805 hasIssue "7" @default.
• W4384694805 hasLocation W43846948051 @default.
• W4384694805 hasLocation W43846948052 @default.
• W4384694805 hasLocation W43846948053 @default.
• W4384694805 hasOpenAccess W4384694805 @default.
• W4384694805 hasPrimaryLocation W43846948051 @default.
• W4384694805 hasRelatedWork W120274727 @default.
• W4384694805 hasRelatedWork W160291598 @default.
• W4384694805 hasRelatedWork W1651394837 @default.
• W4384694805 hasRelatedWork W2009263326 @default.
• W4384694805 hasRelatedWork W2041740107 @default.
• W4384694805 hasRelatedWork W2093022913 @default.
• W4384694805 hasRelatedWork W2148670734 @default.
• W4384694805 hasRelatedWork W2185332956 @default.

• next